eribulin mesylate (Halaven)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

GENERIC NAME: eribulin mesylate


DRUG CLASS AND MECHANISM: Eribulin mesylate is a chemotherapeutic medicine approved to treat metastatic breast cancer, an advanced form of breast cancer that has spread to other parts of the body.

Microtubules are dynamic intracellular structures that are responsible for various kinds of movements including cell division, organization of intracellular structure, and intracellular transport. Eribulin inhibits the growth phase of microtubules, consequently interfering with cell growth and function and eventually causing cancer cell death. Eribulin was developed from a chemical first isolated from the rare marine sponge, Halichondria okadai.

Eribulin can help some patients with metastatic breast cancer live longer. In one trial, women treated with eribulin lived about 2.5 months longer than women who received other treatments. Eribulin was approved by the FDA in 2010.

PRESCRIBED FOR: Eribulin is a prescription chemotherapy medicine used to treat patients with metastatic breast cancer. Eribulin should only be used in patients who have already received at least 2 other types of anti-cancer medicines, including an anthracycline and a taxane.

SIDE EFFECTS: The most common side effects of eribulin are:

Quick GuideBreast Cancer Diagnosis and Treatment

Breast Cancer Diagnosis and Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors